Drug Detail

Drug Name Fulvestrant
Trade Name Faslodex
Synonyms ICI 182,780
Drug Descriptions

Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells (NCI Drug Dictionary). Faslodex (fulvestrant) is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov).

DrugClasses Hormone - Anti-estrogens 16

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
Fulvestrant + MK2206
Fulvestrant + BKM120
AZD5363 + Fulvestrant
Fulvestrant + Seribantumab
Enzalutamide + Fulvestrant
Fulvestrant + SAR405838
Trastuzumab + Pertuzumab + Fulvestrant
Fulvestrant + Pembrolizumab
MLN0128 + Fulvestrant
cabozantinib + Fulvestrant
Fulvestrant + Palbociclib + Pictilisib
Erdafitinib + Fulvestrant + Palbociclib
Fulvestrant + Palbociclib + Avelumab
Fulvestrant Faslodex (fulvestrant) is a competitive inhibitor of estrogen that binds and deforms estrogen receptors, and causes inhibition of growth in cultured estrogen-sensitive breast cancer cells (NCI Drug Dictionary). Faslodex (fulvestrant) is FDA approved for use in patients with hormone receptor-positive breast cancer (FDA.gov).
Fulvestrant + THZ1
Fulvestrant + Neratinib
Fulvestrant + Olaparib + Palbociclib
Fulvestrant + MCLA-128
AZD8835 + Fulvestrant + Palbociclib
Fulvestrant + Taselisib
Fulvestrant + REGN2878-DM1
BKM120 + Fulvestrant + LEE011
GSK525762 + Fulvestrant
Fulvestrant + Lapatinib
Atezolizumab + Ipatasertib + Fulvestrant
Fulvestrant + Ixazomib
Danusertib + Fulvestrant
Fulvestrant + Everolimus
Alisertib + Fulvestrant
Anastrozole + Fulvestrant
Fulvestrant + Trametinib
Fulvestrant + Palbociclib
Fulvestrant + Pictilisib
Fulvestrant + Ribociclib
Fulvestrant + Letrozole + Palbociclib
GDC-0077 + Fulvestrant
Debio 1347 + Fulvestrant
Fulvestrant + talimogene laherparepvec
Fulvestrant + Venetoclax
Fulvestrant + JNJ-7706621
Fulvestrant + Everolimus + Anastrozole
Abemaciclib + Fulvestrant
Bosutinib + Fulvestrant + Palbociclib
Vistusertib + Fulvestrant
Fulvestrant + Lucitanib
Fulvestrant + Selumetinib
GS-5829 + Fulvestrant
Fulvestrant + VX-11e
Dasatinib + Fulvestrant
Atezolizumab + Bevacizumab + Fulvestrant
Abemaciclib + Fulvestrant + Xentuzumab
Fulvestrant + PDR001 + Ribociclib
Fulvestrant + Dovitinib
BYL719 + Fulvestrant + LEE011
AZD8835 + Fulvestrant
Alpelisib + Fulvestrant
Atezolizumab + Fulvestrant
Everolimus + Fulvestrant + Neratinib